(TNDM) Tandem Diabetes Care - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.026m USD | Total Return: -32.3% in 12m
Avg Turnover: 39.3M
Qual. Beats: 1
Rev. Trend: 82.8%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -9.1 is critical
Altman Z'' -1.79 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Tandem Diabetes Care, Inc. (TNDM) is a medical technology company specializing in automated insulin delivery systems for diabetes management. Its primary hardware portfolio includes the t:slim X2 and the Tandem Mobi insulin pumps, supported by a recurring revenue model through the sale of disposable cartridges and infusion sets.
The company integrates software solutions such as the Tandem Source data platform and the Sugarmate mobile app to provide users with visual therapy analytics. As part of the Health Care Equipment sector, Tandem operates in a highly regulated market where growth is driven by the transition from manual injections to automated, closed-loop systems that integrate with continuous glucose monitors (CGMs).
Tandem maintains a research collaboration with the University of Virginia Center for Diabetes Technology to advance automated insulin delivery algorithms. Investors may find it useful to examine ValueRay for further data on the companys market position. Headquartered in San Diego, the firm serves both domestic and international markets.
- Tandem Mobi adoption rates drive market share expansion in automated insulin delivery
- High-margin cartridge and infusion set recurring revenue fuels long-term profitability
- Integration with multiple continuous glucose monitoring systems increases competitive differentiation
- International expansion and global reimbursement rates impact top-line revenue growth
- Research and development spending on closed-loop technology affects short-term operating margins
| Net Income: -94.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 7.04 > 1.0 |
| NWC/Revenue: 62.20% < 20% (prev 34.04%; Δ 28.16% < -1%) |
| CFO/TA 0.02 > 3% & CFO 19.6m > Net Income -94.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.4m) vs 12m ago 3.00% < -2% |
| Gross Margin: 54.93% > 18% (prev 0.47%; Δ 5.45k% > 0.5%) |
| Asset Turnover: 99.01% > 50% (prev 119.5%; Δ -20.52% > 0%) |
| Interest Coverage Ratio: -9.12 > 6 (EBITDA TTM -63.2m / Interest Expense TTM 8.88m) |
| A: 0.55 (Total Current Assets 887.1m - Total Current Liabilities 248.0m) / Total Assets 1.15b |
| B: -1.10 (Retained Earnings -1.27b / Total Assets 1.15b) |
| C: -0.08 (EBIT TTM -81.0m / Avg Total Assets 1.04b) |
| D: -1.24 (Book Value of Equity -1.27b / Total Liabilities 1.02b) |
| Altman-Z'' = -1.79 = D |
| DSRI: 1.19 (Receivables 140.7m/126.6m, Revenue 1.03b/1.10b) |
| GMI: 0.85 (GM 54.93% / 46.57%) |
| AQI: 0.89 (AQ_t 0.08 / AQ_t-1 0.09) |
| SGI: 0.93 (Revenue 1.03b / 1.10b) |
| TATA: -0.10 (NI -94.5m - CFO 19.6m) / TA 1.15b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 14.54 with a total of 2,412,098 shares traded.
Over the past week, the price has changed by +7.46%,
over one month by -26.64%,
over three months by -43.62% and
over the past year by -32.31%.
Tandem Diabetes Care has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold TNDM.
- StrongBuy: 6
- Buy: 4
- Hold: 10
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 30.5 | 109.9% |
P/E Forward = 1111.1111
P/S = 0.9981
P/B = 7.743
Revenue TTM = 1.03b USD
EBIT TTM = -81.0m USD
EBITDA TTM = -63.2m USD
Long Term Debt = 601.8m USD (from longTermDebt, last quarter)
Short Term Debt = 20.1m USD (from shortTermDebt, last quarter)
Debt = 867.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 133.0m
Net Debt = 297.4m USD (calculated: Debt 867.7m - CCE 570.3m)
Enterprise Value = 1.32b USD (1.03b + Debt 867.7m - CCE 570.3m)
Interest Coverage Ratio = -9.12 (Ebit TTM -81.0m / Interest Expense TTM 8.88m)
EV/FCF = -72.96x (Enterprise Value 1.32b / FCF TTM -18.1m)
FCF Yield = -1.37% (FCF TTM -18.1m / Enterprise Value 1.32b)
FCF Margin = -1.76% (FCF TTM -18.1m / Revenue TTM 1.03b)
Net Margin = -9.20% (Net Income TTM -94.5m / Revenue TTM 1.03b)
Gross Margin = 54.93% ((Revenue TTM 1.03b - Cost of Revenue TTM 463.1m) / Revenue TTM)
Gross Margin QoQ = 55.33% (prev 57.67%)
Tobins Q-Ratio = 1.15 (Enterprise Value 1.32b / Total Assets 1.15b)
Interest Expense / Debt = 1.02% (Interest Expense 8.88m / Debt 867.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -64.0m (EBIT -81.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.88 (Total Current Assets 887.1m / Total Current Liabilities 307.8m)
Debt / Equity = 6.55 (Debt 867.7m / totalStockholderEquity, last quarter 132.4m)
Debt / EBITDA = -4.71 (negative EBITDA) (Net Debt 297.4m / EBITDA -63.2m)
Debt / FCF = -16.40 (negative FCF - burning cash) (Net Debt 297.4m / FCF TTM -18.1m)
Total Stockholder Equity = 138.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.11% (Net Income -94.5m / Total Assets 1.15b)
RoE = -6.70% (Net Income TTM -94.5m / Total Stockholder Equity 1.41b)
RoCE = -4.02% (EBIT -81.0m / Capital Employed (Equity 1.41b + L.T.Debt 601.8m))
RoIC = -7.40% (negative operating profit) (NOPAT -64.0m / Invested Capital 865.0m)
WACC = 5.61% (E(1.03b)/V(1.89b) * Re(9.67%) + D(867.7m)/V(1.89b) * Rd(1.02%) * (1-Tc(0.21)))
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 2.03%
[DCF] Fair Price = unknown (Cash Flow -18.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.34 | # QB: 1
Revenue Correlation: 82.80 | Revenue CAGR: 15.62% | SUE: 0.15 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.33 | Chg30d=-13.35% | Revisions=-40% | Analysts=19
EPS next Quarter (2026-09-30): EPS=-0.19 | Chg30d=-17.65% | Revisions=-52% | Analysts=19
EPS current Year (2026-12-31): EPS=-0.70 | Chg30d=+12.05% | Revisions=+33% | GrowthEPS=+72.9% | GrowthRev=+5.8%
EPS next Year (2027-12-31): EPS=0.05 | Chg30d=N/A | Revisions=+47% | GrowthEPS=+107.5% | GrowthRev=+12.3%
[Analyst] Revisions Ratio: -52%